$LQDA

Bloch Stephen M sold $26.6M of LQDA (indirect holdings)

Bloch Stephen M sold 388,223 indirectly-held shares of Liquidia Corp (LQDA) at an average of $68.61 ($64.48–$72.41, $26.63M total) across 10 trades over 2026-06-10 to 2026-06-11.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 12, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosure can influence short-term sentiment and positioning, but it does not provide new information about Liquidia’s pipeline, financial results, or regulatory status.

02

Market read

A director sold ~$26.6M of LQDA stock across 10 trades at prices ranging from ~$64.48 to ~$72.41.

03

What to watch

The filing notes indirect ownership and that a pre-arranged 10b5-1 plan was not used; traders may over-interpret intent without additional context (taxes, diversification, estate planning).

Relevance 7/10Novelty 8/10Timing: today’s SEC Form 4 filing (filed 2026-06-12)

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp, detailing a director’s open-market sale of shares.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia Corp director Stephen M. Bloch sold $26.63M of LQDA shares via open-market transactions (Form 4, indirect holdings).

Expected impact

Likely modest downward pressure or increased caution around LQDA, with limited follow-through unless additional company-specific news emerges.

Evidence & confidence

The article is a primary SEC Form 4 disclosure of a large sale ($26.6M) by a director, but it does not indicate why the sale occurred (no 10b5-1 plan stated) or any new operating/regulatory development.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Large insider sales can be routine liquidity/portfolio rebalancing and may not reflect deteriorating fundamentals, especially when trades are spread across multiple days.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Stephen M. Bloch

    Director who sold 388,223 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient